These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 7904547)

  • 41. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.
    Schrezenmeier E; Dörner T
    Nat Rev Rheumatol; 2020 Mar; 16(3):155-166. PubMed ID: 32034323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs.
    Scherak O; Popp W; Kolarz G; Wottawa A; Ritschka L; Braun O
    J Rheumatol; 1993 Jun; 20(6):944-9. PubMed ID: 8102405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients.
    van Kerckhove C; Giannini EH; Lovell DJ
    Arthritis Rheum; 1988 Oct; 31(10):1252-8. PubMed ID: 3178907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice.
    Comer M; Scott DL; Doyle DV; Huskisson EC; Hopkins A
    Br J Rheumatol; 1995 Oct; 34(10):966-70. PubMed ID: 7582705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics of oral and injectable gold compounds.
    Blocka KL; Paulus HE; Furst DE
    Clin Pharmacokinet; 1986; 11(2):133-43. PubMed ID: 3082559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Possible mechanisms of action of antimalarials in rheumatic disease.
    Cutler DJ
    Agents Actions Suppl; 1993; 44():139-43. PubMed ID: 8372722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparative effectiveness of the basic drugs used in rheumatoid arthritis (long-term randomized study)].
    Tsvetkova ES
    Ter Arkh; 1985; 57(8):40-3. PubMed ID: 3934779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs).
    van Gestel AM; Haagsma CJ; Furst DE; van Riel PL
    Baillieres Clin Rheumatol; 1997 Feb; 11(1):65-82. PubMed ID: 9088525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis.
    McLachlan AJ; Tett SE; Cutler DJ; Day RO
    Br J Rheumatol; 1994 Mar; 33(3):235-9. PubMed ID: 8156285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological studies of antigen-induced arthritis in BALB/c mice. II. The effects of second-line antirheumatic drugs and cytotoxic agents on the histopathological changes.
    Hunneyball IM; Crossley MJ; Spowage M
    Agents Actions; 1986 Jun; 18(3-4):394-400. PubMed ID: 2875633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis.
    Runge LA
    Am J Med; 1983 Jul; 75(1A):52-6. PubMed ID: 6869411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells.
    Deleuran B; Kristensen M; Paludan K; Zachariae C; Larsen CG; Zachariae E; Thestrup-Pedersen K
    Cytokine; 1992 Sep; 4(5):403-9. PubMed ID: 1358240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Slow-acting antirheumatic drugs in chronic arthritis of childhood.
    Grondin C; Malleson P; Petty RE
    Semin Arthritis Rheum; 1988 Aug; 18(1):38-47. PubMed ID: 2903554
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy of standard slow-acting antirheumatic drugs.
    Epstein WV
    Semin Arthritis Rheum; 1994 Jun; 23(6 Suppl 2):32-8. PubMed ID: 7939729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simple and simultaneous determination of sulphapyridine and acetylsulphapyridine in human serum by column-switching high-performance liquid chromatography.
    Teshima D; Hino B; Itoh Y; Oishi R
    J Clin Pharm Ther; 2002 Dec; 27(6):403-8. PubMed ID: 12472979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transcription factors AP-1 and NF-kappa B: where steroids meet the gold standard of anti-rheumatic drugs.
    Handel ML
    Inflamm Res; 1997 Aug; 46(8):282-6. PubMed ID: 9297571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.